Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2012

01-07-2012 | Clinical trial

Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer

Authors: Elisabetta Munzone, E. Botteri, A. Sciandivasci, G. Curigliano, F. Nolè, M. Mastropasqua, N. Rotmensz, M. Colleoni, A. Esposito, L. Adamoli, A. Luini, A. Goldhirsch, G. Viale

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Login to get access

Abstract

The aim of this analysis was to investigate the usefulness of Ki-67 labeling index (LI) for the identification of different prognostic subgroups in primary node-negative, triple negative breast cancer (TNBC) patients. From January 1997 to December 2005, 1,053 patients operated for TNBC were identified through the institutional clinical database. The study was performed in accordance with REMARK criteria. The relationship between Ki-67LI and the risk of breast-related deaths was evaluated with a multivariable Cox regression model. Cubic splines were used to model Ki-67LI as a continuous variable. We selected 496 consecutive patients with node-negative TNBC. Median age was 52 years, median Ki-67LI 48 % (range 4–95), and median follow up 6 years (range 0.5–13). Total deaths and deaths from BC were 52 (10.5 %) and 38 (7.7 %), respectively. Ki-67LI increased with decreasing age (P < 0.01), increasing tumor size (P < 0.01), and grade (P < 0.01). When analyzing Ki-67LI as a continuous variable, the risk of death from BC increased steeply with increasing Ki-67LI up to about 35 % and remained flat for higher values (adjusted effect of Ki-67 P = 0.049; adjusted nonlinear effect P = 0.021). Accordingly, when dividing patients into lower (≤35 %) and higher (>35 %) Ki-67LI subgroups, the 5-year cumulative incidence of breast-related deaths were 2.3 and 9.0 %, respectively, with an adjusted HR>35 vs ≤35 of 2.3 (95 % CI 1.0–5.8, P = 0.046). Within the group of patients with node-negative TNBC, Ki-67LI was associated with different prognoses subgroups. Ki-67LI might be useful in the design of trials of risk-adapted adjuvant therapies.
Literature
1.
go back to reference Gluz O, Liedtke C, Gottschalk N et al (2009) Triple negative breast cancer—current status and future directions. Ann Oncol 20:1913–1927PubMedCrossRef Gluz O, Liedtke C, Gottschalk N et al (2009) Triple negative breast cancer—current status and future directions. Ann Oncol 20:1913–1927PubMedCrossRef
2.
go back to reference Hudis C, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(suppl 1):1–11PubMedCrossRef Hudis C, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(suppl 1):1–11PubMedCrossRef
3.
go back to reference Adamo B, Anders CK (2011) Stratifying triple-negative breast cancer: which definition(s) to use? Breast Cancer Res 13:105PubMedCrossRef Adamo B, Anders CK (2011) Stratifying triple-negative breast cancer: which definition(s) to use? Breast Cancer Res 13:105PubMedCrossRef
4.
go back to reference Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376PubMedCrossRef Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376PubMedCrossRef
5.
go back to reference Prat A, Parker J, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68PubMedCrossRef Prat A, Parker J, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68PubMedCrossRef
6.
go back to reference Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28):7212–7220PubMedCrossRef Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28):7212–7220PubMedCrossRef
7.
go back to reference Petit T, Wilt M, Velten M et al (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205–211PubMedCrossRef Petit T, Wilt M, Velten M et al (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205–211PubMedCrossRef
8.
go back to reference Pohl G, Rudas M, Taucher S et al (2003) Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 78:97–103PubMedCrossRef Pohl G, Rudas M, Taucher S et al (2003) Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 78:97–103PubMedCrossRef
9.
go back to reference Brown RW, Allred CD, Clark GM et al (1996) Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2:585–592PubMed Brown RW, Allred CD, Clark GM et al (1996) Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2:585–592PubMed
10.
go back to reference Weikel W, Brumm C, Wilkens C, Beck T, Knapstein PG (1995) Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev 19:446–450PubMed Weikel W, Brumm C, Wilkens C, Beck T, Knapstein PG (1995) Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev 19:446–450PubMed
11.
go back to reference Rhee J, Han SW, Oh DY et al (2008) The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 8:307PubMedCrossRef Rhee J, Han SW, Oh DY et al (2008) The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 8:307PubMedCrossRef
12.
go back to reference Dowsett M, Nielsen TO, A’hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103:1656–1664PubMedCrossRef Dowsett M, Nielsen TO, A’hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103:1656–1664PubMedCrossRef
13.
go back to reference Hernandez-Aya LF, Chavez-MacGregor M, Lei X et al (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29:2628–2634PubMedCrossRef Hernandez-Aya LF, Chavez-MacGregor M, Lei X et al (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29:2628–2634PubMedCrossRef
14.
go back to reference McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRef McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRef
15.
go back to reference Rosen PP, Oberman H (1993) Tumors of the mammary gland. Armed Forces Institute of Pathology, Washington, DC Rosen PP, Oberman H (1993) Tumors of the mammary gland. Armed Forces Institute of Pathology, Washington, DC
16.
go back to reference Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41:151PubMedCrossRef Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41:151PubMedCrossRef
17.
go back to reference Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef
18.
19.
go back to reference Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef
20.
go back to reference Keam B, Im SA, Lee KH et al (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13:R22PubMedCrossRef Keam B, Im SA, Lee KH et al (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13:R22PubMedCrossRef
21.
go back to reference Rakha EA, El-Rehim DA, Paish C et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42:3149–3156PubMedCrossRef Rakha EA, El-Rehim DA, Paish C et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42:3149–3156PubMedCrossRef
22.
go back to reference Yamamoto Y, Ibusuki M, Nakano M et al (2009) Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 16:260–267PubMedCrossRef Yamamoto Y, Ibusuki M, Nakano M et al (2009) Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 16:260–267PubMedCrossRef
23.
go back to reference Munzone E, Curigliano G, Burstein HJ et al (2012) CMF revisited in the 21st century. Ann Oncol 23(2):305–311PubMedCrossRef Munzone E, Curigliano G, Burstein HJ et al (2012) CMF revisited in the 21st century. Ann Oncol 23(2):305–311PubMedCrossRef
25.
go back to reference Wirapati P, Sotiriou C, Kunkel S et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65PubMedCrossRef Wirapati P, Sotiriou C, Kunkel S et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65PubMedCrossRef
Metadata
Title
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer
Authors
Elisabetta Munzone
E. Botteri
A. Sciandivasci
G. Curigliano
F. Nolè
M. Mastropasqua
N. Rotmensz
M. Colleoni
A. Esposito
L. Adamoli
A. Luini
A. Goldhirsch
G. Viale
Publication date
01-07-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2040-6

Other articles of this Issue 1/2012

Breast Cancer Research and Treatment 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine